Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

40.0%

4 terminated/withdrawn out of 10 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

125%

5 of 4 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 1

4(40.0%)

Phase 2

4(40.0%)

Phase 3

2(20.0%)

10Total

Phase 1(4)

Phase 2(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07401823Phase 2Enrolling By Invitation

Open-Label Extension Study to Pioneer Study 6058-SCD-101

Role: lead

NCT07431398Phase 1Recruiting

Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease

Role: lead

NCT05169580Phase 1Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir

Role: lead

NCT04004000Phase 2Terminated

Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension

Role: lead

NCT05397470Phase 3Terminated

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

Role: lead

NCT04264442Phase 2Terminated

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

Role: lead

NCT04003974Phase 2Completed

Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

Role: lead

NCT04511819Phase 3Terminated

Losmapimod Safety and Efficacy in COVID-19

Role: lead

NCT04586985Phase 1Completed

Safety, Tolerability and Pharmacokinetics of FTX-6058

Role: lead

NCT05002231Phase 1Completed

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

Role: lead

All 10 trials loaded